Merci, Sylvie. Good afternoon, everyone, and thank you for joining us today.

Our comments will focus on the financial results of our first quarter which ended on December 23. With me today is Mr.

Eric La Flèche, President and CEO; and François Thibault, Executive VP and CFO. During the call, we will present our first quarter results and comment on its highlights.

We will then be happy to take your questions. Before we begin, I would like to remind you that we will use in today’s discussion different statements that could be referred -- that could be construed as forward-looking information.

In general, any statement which does not constitute a historical fact may be deemed a forward-looking statement. Words or expressions such as expect, intend, are competent that will and other similar words or expressions are generally indicative of a forward-looking statement.

The forward-looking statements are based upon certain assumptions regarding the Canadian Food and Pharmaceutical industries, the general economy, our annual budget and our 2024, 2025 action plan. These forward-looking statements do not provide any guarantees as to the future performance of the company and are subject to potential risks, known and unknown, as well as uncertainties that could cause the outcome to differ materially.

Risk factors that could cause actual results or events to differ materially from our expectations as expressed in or implied by our forward-looking statements are described under the Risk Management Section in our 2023 annual report. We believe these forward-looking statements to be reasonable and pertinent at this time and represent our expectations.

The company does not intend to update any forward-looking statements except as required by applicable law. I will now turn the call over to François.

Thank you, Sharon, and good afternoon, everyone. For the quarter, total sales reached $4.974 billion, an increase of 6.5% versus the same period last year.

Food same-store sales were up 6.1% and sales were positively impacted as the week preceding Christmas fell in the first quarter, whereas last year it fell in the second quarter. When we adjust for the Christmas shift, that is, when we compare same-store sales for the 12-week period ending December 23, 2023 with the one ending December 24, 2022, Food same-store sales increased by 3.4%.

We will have the reverse effect in the second quarter. Pharma same-store sales were up 3.9% when comparing the 12-week period ending December 23, 2023 with the one ending December 24, 2022.

Our gross margin stood at 19.6% of sales, same as in the first quarter last year. Operating expenses amounted to $506.4 million, up 10.5% versus last year.

Operating expenses as a percent of sales was 10.2% versus 9.8% in the same quarter last year. As expected, the higher ratio is mainly due to the commissioning of our new automated DC for fresh and frozen products in Terrebonne as we incur temporary duplication of costs and learning curve inefficiencies.

We also have higher third-party e-com fees than last year. EBITDA for the quarter totaled $468.1 million, up 1.2% year-over-year and up 2% when removing the gains on disposal of assets.

Total depreciation and amortization expense for the quarter was $131.1 million, up $11 million versus last year, a significant portion of the increase is due to our new Terrebonne DC. Net financial costs for the first quarter were $32.4 million, compared with $27.1 million for the corresponding quarter of 2023 and the increase is mainly due to an increase in debt, higher interest rates and lower capitalized interest related to our distribution center automation projects.

Our effective tax rate stood at 25% versus 26.5% last year, reflecting a favorable tax adjustment in respect of prior years. Adjusted net earnings were $235 million, compared to $237.6 million last year, a 1.1% decrease, and our adjusted net earnings per share amounted to $1.02, up 2% versus last year adjusted EPS of $1.

After 12 weeks in fiscal 2024, capital expenditures amounted to $117.3 million versus $129.3 million last year. On the retail side, during the first quarter, we opened three Super C stores and carried out major expansions and renovations of four stores for a net increase of 88,400 square feet or 0.4% of our food retail network.

Turning to in-store technology, we ended the quarter with 502 Food stores and 63 Pharmacies equipped with self-checkout technology. As for electronic shelf labels, at the end of Q1, we had 345 Food stores and 46 Pharmacies equipped with that technology.

Under our Normal Course Issuer Bid program, as of January 19th of this year, we have repurchased 1.675 million shares for a total consideration of $113.7 million, representing an average share price of $68.89. The Board of Directors yesterday declared a quarterly dividend of $0.335 a share or $1.34 on an annual basis, an increase of 10.7% versus last year.

This is the 30th consecutive year of dividend growth and represents a payout of about 30% of last year’s adjusted net earnings in line with our policy. In closing, our first quarter results are tracking well to the guidance we provided in November for fiscal 2024, that is EBITDA to grow by less than 2% versus the level reported in fiscal 2023, and adjusted net earnings to be flat to down $0.10 versus the level reported in fiscal 2023.

That’s it for me. I’ll now turn it over to Eric.

Thank you, François, and good afternoon, everyone. We recorded solid results in the first quarter as our teams continued to deliver good value to customers in all our Food and Pharmacy banners.

Total sales grew by 6.5%, EBITDA by 1.3% and adjusted EPS by 2%. As expected, our results were impacted by the commissioning of our new automated DC for fresh and frozen products in Terrebonne.

The transition from our other facilities is causing some duplication of expenses and loss of efficiency, but the good news is, as François said, we are on track with our plan and with the guidance we gave you in November. As François also mentioned, Food same-store sales were up 6.5% and when adjusted for the Christmas shift, same-store sales were up 3.4%.

Our internal food basket inflation decelerated to about 4%, lower than the reported CPI and down from 5.5% in the previous quarter. For the quarter, our tonnage -- our Food tonnage was up, with higher transaction counts, while the average basket remained stable overall.

Promotional penetration remained high and private label sales continued to outpace national brands. We are very pleased with the performance of our discount Food stores.

We opened three new Super Cs during the quarter, with very encouraging early results. This brings the total to 106 Super C stores.

Over the last 15 months, we opened nine new discount stores in Quebec and Ontario and another four are scheduled to open this fiscal year. Our online Food sales grew by 105% versus last year, while the market was stable.

Growth continued to be fueled by third-party partnerships and the expansion of click-and-collect to our discount banners. As we begin to lap the start of these initiatives, we expect the year-over-year growth of online sales to moderate over the coming quarters.

Total Pharmacy comp sales were up 3.9%, on top of 7.7% in the first quarter last year. Prescription sales were up a strong 6.6%, driven by professional services and specialty medications.

Commercial sales were down 1.2% in the quarter, as OTC sales declined compared to exceptionally high demand for cough and cold products last year. This was partly offset by continued growth in cosmetics and HABA.

We continue to be pleased with our Moi loyalty program. We have now reached over 2.5 million active members, more than double the size of Metro&Moi.

Member swipe rates, loyalty sales penetration and member engagement rates continue to grow across all banners and have surpassed all past program metrics for Metro&Moi at Metro and Air Miles at Jean Coutu. We see cross-shop spending and visits increasing, with potential for more as we leverage our personalization capabilities.

Coming back to our Terrebonne automated DC, during the quarter we completed the transfer of all frozen products, as well as fresh seafood. We are currently transitioning fresh meat and deli products, and as I said, productivity in the facility is tracking the business plan, as our teams are leveraging our experience from the commissioning of our DCs in Toronto.

Going forward, the cost increases received from the big CPG companies will start to be reflected in retail prices in February. The number of increases will be more normal than the peak we saw during the last two years.

On the Pharmacy side, we will be going up against -- tough comps again in our second quarter, as we continue to lap extraordinary demand in OTC medication due to post-COVID cough and cold symptoms last year. To conclude, last month we published our Annual Corporate Responsibility Report, which improved disclosure and additional targets.

We believe that our approach to corporate responsibility is an asset in realizing our purpose to nourish the health and well-being of our communities and in creating long-term value for our shareholders. That’s it for me.

Thank you and we’ll be happy to take your questions now.

Hey. Thanks, and good afternoon, everyone.

Eric, from your commentary, it sounds as though we’re really seeing a continuation both of competitive intensity and of consumer behavior for calendar Q4, your fiscal Q1. I guess, is that a fair statement and have you seen any changes Q1 to-date?

I think that’s a fair assessment. That’s what we’re seeing.

It’s pretty consistent, like, I tried to describe, but it’s highly promotional as it was. There’s some trading down going on.

Private label sales are continuing to grow at a much faster clip than national brands and discount -- the shift to discount continues to happen. So very similar to the previous quarter, yes.

That’s great. Thank you.

And you also mentioned price increases, we’ve heard from some of your peers that domestic suppliers, the price increase requests have been more modest, but the big multinationals still being kind of aggressive. Can you talk about what we should be thinking around pricing in 2024?

So like I said in my opening statement, post-cost freeze, which starts next week, some prices at retail will start to increase. The good news is the number of increases is going back to more normal levels compared to what we saw in the last two years.

So there’s a substantial reduction in the number of requests. The size of the request varies, but the general average is certainly lower than what we saw last year.

So I don’t have a precise number, but I think we’re returning to more normal inflation levels gradually. So mid-single-digit, for some categories a little less than that, for some categories higher than that.

Some other commodity-driven categories can be even more than that, but those are more exceptions. So, in general, it’s trending better, trending towards normal, but still higher than normal.

That’s great. Thank you.

Great. Thanks for the question.

I wanted to ask about the ramp of the DCs. So, as I recall, for Toronto Phase One, I believe that was completed over a span of, I think, about two years or so, and what you’re launching in this fiscal year is a lot larger in scope.

So can you help us understand or just remind us, I guess, what gives you the confidence that you can stand up all of this in this one year, is it because the technologies and the equipment in Terrebonne are the same as what was in Toronto Phase One. So you’re viewing this year’s ramp as a bit of a rinse and repeat, even though it is larger in scope?

Yes. For sure, there’s a lot of learnings from what happened in Toronto.

Toronto fresh Phase One was the first project. We then followed up with the freezer, which went better.

And now the third one is the big one in Quebec, which is fresh and frozen. So this fall, it was very focused on frozen.

So it was a comparable ramp-up startup than what we did with our frozen project in Toronto and we started fresh seafood towards the end of the quarter, took a pause for the holidays, and now in January, we’re back with fresh meat and deli that’s going to take place over the next several weeks. So for sure, it’s a big project.

That’s why we talked about headwinds and the extra expenses that we incur to start up a big building like that. But a lot of learnings from the Toronto project, a lot of our teams here in Quebec went to Toronto to work in the startup over there.

So everything’s going faster and better, so -- and we plan for it. So the budgets we made, the plans we made and the guidance we gave you were based on better, quicker ramp-ups here in Montreal and we’re tracking on plan.

So we’re very pleased with that. It’s a huge effort by a lot of people here, but so far it’s going well.

Okay. That’s good to hear.

And my follow-up is on Pharmacy, When I look at Jean Coutu over the years, I don’t see much unit growth. I recall at your Investor Day last year, you alluded to wanting to invest more in, I believe it was the HABA aspect for front of store.

But can you just remind us right now, how are you thinking about your overall strategy for Pharmacy over the medium- to long-term? Thanks.

So we are the lead player in Pharmacy in Quebec with Jean Coutu, the clear leader and Brunet. So we have a two-banner strategy.

We have close to 670 pharmacies. So we’re not adding units as much as growing organically with our current network.

So we’ve optimized the network. There were a few conversions to Jean Coutu and -- so our focus is very much on growing organically, growing sales, front store and HABA in the existing fleet.

That’s more than growing the store count. So professional services are certainly growing.

First line of the healthcare system is a big part of our strategy. All the digital work that we can do to increase customer engagement is going to be happening at Jean Coutu.

So there’s a big digital component of the lab that’s already in place and we’re going to build on that to increase our digital connections for commercial sales in the front end with our Moi program. So we like our position.

We like the structural demand, the demographics for pharmacy, especially in Quebec, and we -- as a clear leader, we’re well positioned to do well.

Great. Thank you.

Yeah. Good afternoon, Eric and François.

I just wanted to follow up on the pricing discussion. So Food CPI in the U.S.

and Canada seems to be a pretty significant difference. I just wanted to get your take on that.

Do you see that as a kind of a five-month to six-month lag and we’re back to the U.S. levels or do you think there’s something more structural in Canada that keeps the Canadian inflation running kind of well above the 2% to 3% range this year?

Well, there are some structural differences between the two countries, some regulated markets in Canada that you don’t necessarily see in the U.S. So that’s contributing to a higher structural rate of inflation, but it’s not that material.

I think the good news is here that, the year-over-year inflation rate is coming down, month-over-month prices have stabilized over the last few months and the year-over-year number keeps coming down, certainly, quarter -- every quarter. So pleased with that.

The increases we’re getting, like I said, they’re still coming in lower quantities and lower prices, but it’s still going to cause inflation we expect in the next year, albeit at more normal levels. We always say more normal is 2% to 3%.

We’re not quite there yet, but we’re getting there.

Okay. Well, thanks for that.

And I just want to talk about the front store, the negative comp there. First off, was there an impact at all from the Christmas week in there and can you talk a little bit about how the cosmetics and how volumes trended and how soon can we maybe get back to those kind of low-single digits, mid-single-digit cadence there?

So the front store number we gave you for Pharmacy is perfectly comparable. So there’s no Christmas effect on that.

And so a couple of things, last year, as I tried to explain, front store sales were high at 10%, very strong OTC demand. This was post-COVID symptoms, trifecta, respiratory COVID, influenza, name it.

There was a lot of cough and cold symptoms last fall and we were comping that and the cough and cold season started later this year. So there’s less OTC demand this year.

That is the biggest contributor to the decline. It’s a decline in OTC, which as you know, generates traffic into pharmacy and may have an impact on the rest of the front store.

So that’s the biggest one. If I look at Q2 with the cough and cold season now permanently in place, even if we comp good high numbers in front end in Q2, we’re seeing better trends because of the cough and cold.

One other factor I might add for Q1, for those of you who don’t live in Quebec, there was a significant public sector strike for several weeks. Teachers and then for several days, general strikes.

So disposable income in November, December in this province was not where it used to be. So that had an impact a bit on seasonal sales.

So hopefully that’s all behind us.

Yeah. That’s helpful.

Just one last one. Yeah.

Thanks for that. Maybe if I could just ask one quick one.

Without really getting into specific numbers, but just order of magnitude, perhaps maybe in terms of timing. I think you mentioned in your Investor Day that you expect Terrebonne to be fully ramped up in Q2, Q3 this fiscal year and I think fresh to buy Q1 next fiscal year.

Should we expect, like, a full margin contribution from everything that played out by Q1 fiscal 2025? Is that fair?

Well, Terrebonne started in Q1. We’re transitioning and we’re in Q2 and we’re still transitioning.

So we’re not going to be all done and perfectly productive by the end of Q3. We said, it’s going to take all of this fiscal year to get this thing started up.

So Q1 next year is more the number where we should be in good shape. Phase Two Toronto fresh, we start in June or thereabouts.

So it’s going to be a ramp up there all summer. We expect it to go well, but ramping up is ramping up.

So I hope I can get back to you on the exact timing there, but that too is going to take a few months. So is it before Christmas or slightly around that, I was hoping I can get back to you.

Okay. Thanks, guys.

Hi. Thank you.

When did the Terrebonne DC actually open in Quebec?

It was in October. I don’t have the exact date for you.

Last October.

There -- yeah. There’s a press release on that.

There was…

Great. But I remember you said it was early in October, so.

Yeah.

Okay. So then when should we expect to see peak duplicate overhead costs and peak inefficiencies?

Well, Michael, we’re seeing it now. In Q1, we are basically at the peak in terms of duplication, learning curve deficiencies and so forth.

It’s going to continue throughout the year, but I believe everything else according to plan, you should start to see some improvement on that front as the year progresses. But then we have this fresh Phase Two that’s going to start.

So we’re going to have that overlap. And as Eric said, by the first quarter of next year, we expect that most of those duplicate headwinds and deficiencies will be behind us.

Some expenses will remain, like depreciation, that’s not going away. But the increase next year will be much more manageable year-over-year than what we’re seeing today.

So we’re living it now in terms of the peak.

Okay. Because I was just trying to understand if you started it, if you opened it late October and you only had, say, two months versus three months in Q2, is it possible that the duplicate overhead costs are actually -- and inefficiencies, for that matter, are actually higher in Q2?

It would be a similar picture, to be honest, it’s still a very compressed timeframe, Q1, Q2, that’s where the bulk of it will be and then we’re going to see some improvements as the year progresses.

Okay. Perfect.

Your CapEx was quite low in the first quarter, despite your guidance for CapEx to be over $800 million for the year. So why is -- I would have thought CapEx would have been high to start the year, given everything’s opening, but what should we expect, are we still expecting over $800 million for the full year?

Yeah. So I’m not changing it right now.

We’ll see where we are in Q2. It -- some of it is very choppy in terms of where it falls a quarter or say, second quarter.

So no change for now, but I will update you as we go forward.

Okay. And then just finally, I know you mentioned the discounts still growing faster than conventional, but are you seeing growth in conventional as inflation slows?

Are we seeing any change in the pace of growth in conventional?

No. I don’t think we could say that.

Clearly, there’s a lot more growth on the discount side. Our -- we’re pleased with the growth or levels that we’re seeing in conventional.

We have some growth, but it hasn’t changed. That’s the question.

So I’m trying to answer on a relative basis. That said, we’re pleased with our relative performance in conventional in both of our markets.

So we look at the Nielsen numbers every week and we’re trending okay. But the growth is more on the discount side.

Yeah. Thank you.

Yeah. Good afternoon.

Just to follow up on that last topic. Eric, would you say that the sales performance gap between discount and conventional is stable?

Is it growing or is it narrowing?

It’s stable. It varies by region.

There’s a change in the market. There’s some conversions happening at a pretty rapid clip.

So the size of the discount pie is growing. So that creates a mathematical growth on the discount side in Quebec.

In Ontario, I would say that the discount market growth is a lot more stable, but it’s -- again, it’s higher than conventional.

Yeah. Understood.

Okay. Thanks.

And then I know you don’t give gross margin, obviously, by segment. But any commentary you could provide just anecdotally about the relative performance would be helpful and I’m guessing the timing shift didn’t really affect the consolidated rate much at all, but maybe a slight tailwind.

I don’t know if you have any comment there.

Yeah. So, Mark, it’s François here.

It’s pretty flat across banners and divisions. So nothing really stands out from one versus the other.

And you’re right, this shift doesn’t have an impact on that.

Yeah. Okay.

And then just last one, obviously, now there’s some public reports about assets for sale in the Pharmacy sector. Hoping just at a high level, you could address your priorities when you’re evaluating M&A and specifically the relative strategic importance of having a national presence?

Thanks.

Well, like we always say, our M&A engine is always on and we’re looking at opportunities in Food and Pharmacy in Canada. I can’t comment on any specific file.

We look for a strategic fit. We look for value creation for our shareholders long-term.

So those parameters have not changed and we have a balance sheet that can take on significant acquisition if it presents itself.

Yeah. Understood.

Okay. All the best.

Take care.

Hi. Thanks for the questions.

I just want to get some perspective on gross margin and the year-over-year change and can you give me a sense of the puts and takes. For instance, discount was growing, the e-commerce business growing quickly, pressure in front store, OTC and seasonal, which are presumably high margin discount categories.

So it seems to me that all else equal -- and grocery growing quicker than Pharmacy, it seems like all else equal, there should be pressure on gross margins, but you were able to hold it flat. What were the big drivers on the other side and did I get my big factors right in the way I characterized it?

Yeah. But there’s also efficiencies that we have.

We highlighted that last year with the Ontario freezer that we’re able to generate some good efficiencies as well that helps the margins. So it’s not just the mix, it’s also our operational efforts at reducing costs and reducing efficiency.

So all this blended, we were able to keep gross margins stable year-over-year, both Food and Pharmacy.

Okay. So it’s largely the initiatives that you’ve been working on those were -- that was the offsetting factor.

Several initiatives and nothing moves the needle by itself, but all considered, it adds up. But your point about the mix…

Okay.

… are valid as well. Obviously, that goes into the equation.

Okay. And just wanted to get your sense on some of the growth in the Pharmacy business on the professional services side and maybe even on the specialty side.

Wondering if the specific Pharmacy formats that you have are tailored sufficiently to address the growth in these segments in terms of consultation rooms and the like. And if not, is there ability to retrofit your existing locations quickly given the franchise structure, a little bit different than a corporate structure.

So how do we think about your ability to capture that growing market?

That’s a good question. So we’re encouraging our franchisees to expand some space for professional services, and call it, clinic and nurses and those services.

So, in general, there’s good space and we’re well equipped to provide those services and you see it in our sales growth, which as I said was fueled by specialty and services. So we’re doing it.

Will there be more opportunities in the future to do it? Yes, we think so.

So as we renovate some of the Pharmacies, that space will be examined for sure and will be optimized for us, for the pharmacists to capture that demand.

Okay. And in terms of the ability -- your ability to incent the franchisees to renovate their stores, is that a relatively direct process or is it more on their volition and whether they want to proceed or not?

Well, they are franchisees. It’s their store, it’s their business.

So the decision has to be theirs. But we encourage and we help financially and we provide planning services and procurement for all sorts of equipment and real estate and everything.

So -- but at the end of the day, the franchisee is independent, is an owner and it’s his balance sheet and his decision. Again, we work closely with them and we provide all the necessary incentives to keep our network modern.

Thank you.

Thank you.

Good afternoon, everyone. Maybe, François, I’ll just start off with a few modeling type questions.

First one is, is it fair to assume that if we exclude those DC ramp-up costs or inefficiency related to the ramp-up, the SG&A expense rate for the quarter would have been at least stable given that you had some pretty solid topline growth?

Yeah. So I won’t give you a precise breakdown, but if you remove those extra costs and these inefficiencies and so forth, when you also factor in the higher e-com third-party fees that we have, in terms of percentage of sales, it would have been roughly similar to last year.

So you’re right.

Okay. No.

That’s very helpful. And then second modeling question, just maybe on the depreciation and interest expense level for Q1, do you think there is roughly a good run rate for the rest of the year?

Well, I -- last quarter I gave you -- I gave some guidance to say to expect that the total variance in depreciation would be $50 million, including obviously the new site. So we’re about $11 million more this quarter.

That’s three periods out of 13. That’s a run rate of about 47.5, 48.

So we’re on that runway now. There’ll be some CapEx coming a little later, but it’s not, I think, we’re exactly at the runway we gave last November.

Got you. Okay.

And then what was roughly the EPS benefit from the Christmas week shift in the quarter?

Well, we don’t really segregate that week. It’s -- I mean, there’s no surprise, the calendar being what it is because of the way last year fell.

It’s part of our results. We want to be transparent, so we have to be transparent to say, look, that included the full week before Christmas, whereas last year it was in the second quarter.

So we shifted that comparison to be apples-to-apples and you’ll see the reverse in Q2. And when you look at the cumulative results after Q2, this will all be neutralized, obviously.

So, yeah, it’s more sales, more costs and it’s a normal contribution, but we don’t really segregate that. You can do the math, I’m sure you’ll get something that’s.

Yeah. Okay.

That’s fair. And I know you guys get asked this question almost every quarter, but when we again look at your Food same-store sales and just look at the street math and take away your 4% inflation, the implied math would suggest that there was a bit of negative some tonnage, but per Eric’s remarks in the opening, he said there’s positive tonnage.

So I’m just figuring out what is the disconnect and just help us understand. Yeah.

Well, again, the real quarter increase is 6.1% same-store. That’s the -- those are the sales for the quarter.

That’s the fact and the inflation was about 4%. So I can tell you we did increase tonnage.

Now, of course, when you shift the calendar for Christmas, it gets a little closer, but the reality is we are seeing some positive tonnage in our numbers. I would add to that the private label sales growth is inflationary and increases tonnage.

So, net-net, even with the Christmas shift, we think we had Food tonnage growth and…

Okay.

…Nielsen numbers tend to back that.

And is it fair to assume...

No warehouse…

Yeah. Okay.

That’s fair. And just the rising discount square footage that we’ve been seeing in Quebec.

Is it fair to say it’s manageable overall for you guys?

So the square footage, we’re adding square footage. One of our competitors is converting conventional to discount.

So in the same square footage, they’ve added a couple of stores also. But so, yeah, on the square footage growth, it’s manageable.

There is an impact. It varies by region I’ve said this before.

In certain areas, we don’t feel it much. In other areas, we feel it more.

But pretty much what we expected.

That’s great. And maybe a last question just on Pharmacy, there’s been a lot more talks about these high cost specialty drugs having a structural growth tailwind for them.

I think Jean Coutu is participating in that segment as well. But I was just curious to see, from where you sit today, how meaningful of this tailwind do you think are these specialty drugs that are going seem to be quite fast, and from a profitability perspective, given your franchise market structure, do you benefit as much from those growth versus your corporate store?

Thank you.

Well, it’s a growing category. It’s a growing sector, for sure.

There are limits on distribution fees in Quebec because for high cost medicines, there are caps. So we don’t make our full distribution margin on them on a rate basis.

That said, there is some growth. These are generated by the pharmacist.

Again, those are capped also and we make a royalty. So, net-net, it’s a growth area, but it’s not linear with other scripts.

Okay. Thanks very much.

Lower margin than the normal scripts.

Okay. Thank you.

Thank you.

Thank you all for your interest in Metro and please mark your calendars for our second quarter results on April 24th. Thank you.